Literature DB >> 30021702

Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.

Shinji Tanaka1, Yuki Sugiura2, Hisako Saito1, Mai Sugahara1, Yoshiki Higashijima1, Junna Yamaguchi1, Reiko Inagi3, Makoto Suematsu2, Masaomi Nangaku4, Tetsuhiro Tanaka5.   

Abstract

It is unclear whether long-term sodium-glucose cotransporter 2 (SGLT2) inhibition such as that during the treatment of diabetes has deleterious effects on the kidney. Therefore, we first sought to determine whether abnormal glucose metabolism occurs in the kidneys of 22-week-old BTBR ob/ob diabetic mice. Second, the cumulative effect of chronic SGLT2 inhibition by ipragliflozin and 30% calorie restriction, either of which lowered blood glucose to a similar extent, on renal glucose metabolism was evaluated. Mass spectrometry-based metabolomics demonstrated that these diabetic mice exhibited an abnormal elevation in the renal pools of tricarboxylic acid cycle metabolites. This was almost completely nullified by SGLT2 inhibition and calorie restriction. Moreover, imaging mass spectrometry indicated an increased level of the tricarboxylic acid cycle intermediate, citrate, in the cortex of the diabetic mice. SGLT2 inhibition as well as calorie restriction almost completely eliminated citrate accumulation in the cortex. Furthermore, imaging mass spectrometry revealed that the accumulation of oxidized glutathione in the cortex of the kidneys, prominent in the glomeruli, was also canceled by SGLT2 inhibition and calorie restriction. Effects of these beneficial interventions were consistent with improvements in glomerular damage, such as albuminuria, glomerular hyperfiltration, and mesangial expansion. Tubulointerstitial macrophage infiltration and fibrosis were ameliorated only by calorie restriction, which may have been due to autophagy activation, which was observed only with calorie restriction. Thus, chronic SGLT2 inhibition is efficient in normalizing the levels of accumulated tricarboxylic acid cycle intermediates and increased oxidative stress in the kidneys of diabetic mice.
Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  albuminuria; diabetes; diabetic nephropathy; oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 30021702     DOI: 10.1016/j.kint.2018.04.025

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  40 in total

1.  Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.

Authors:  Mai Sugahara; Shinji Tanaka; Tetsuhiro Tanaka; Hisako Saito; Yu Ishimoto; Takeshi Wakashima; Masatoshi Ueda; Kenji Fukui; Akira Shimizu; Reiko Inagi; Toshimasa Yamauchi; Takashi Kadowaki; Masaomi Nangaku
Journal:  J Am Soc Nephrol       Date:  2020-01-29       Impact factor: 10.121

Review 2.  Organelle Stress and Crosstalk in Kidney Disease.

Authors:  Sho Hasegawa; Reiko Inagi
Journal:  Kidney360       Date:  2020-08-07

Review 3.  Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.

Authors:  Tian Gan; Yi Song; Feng Guo; Guijun Qin
Journal:  Mol Biol Rep       Date:  2022-08-24       Impact factor: 2.742

Review 4.  Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.

Authors:  Adriana Marton; Tatsuroh Kaneko; Jean-Paul Kovalik; Atsutaka Yasui; Akira Nishiyama; Kento Kitada; Jens Titze
Journal:  Nat Rev Nephrol       Date:  2020-10-01       Impact factor: 28.314

Review 5.  Ion channels and transporters in diabetic kidney disease.

Authors:  Denisha Spires; Anna D Manis; Alexander Staruschenko
Journal:  Curr Top Membr       Date:  2019-02-18       Impact factor: 3.049

Review 6.  Targeting energy pathways in kidney disease: the roles of sirtuins, AMPK, and PGC1α.

Authors:  Amanda J Clark; Samir M Parikh
Journal:  Kidney Int       Date:  2020-12-08       Impact factor: 10.612

Review 7.  A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.

Authors:  Lucia Del Vecchio; Angelo Beretta; Carlo Jovane; Silvia Peiti; Simonetta Genovesi
Journal:  Drugs       Date:  2021-08-07       Impact factor: 9.546

Review 8.  Autophagic dysfunction of β cell dysfunction in type 2 diabetes, a double-edged sword.

Authors:  Ding Yao; Yang GangYi; Wu QiNan
Journal:  Genes Dis       Date:  2020-03-19

9.  Sodium Glucose Co-Transporter 2 Inhibitor Ameliorates Autophagic Flux Impairment on Renal Proximal Tubular Cells in Obesity Mice.

Authors:  Kazuhiko Fukushima; Shinji Kitamura; Kenji Tsuji; Yizhen Sang; Jun Wada
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

Review 10.  Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy.

Authors:  Jiarong Lv; Yu Wu; Yifeng Mai; Shizhong Bu
Journal:  J Diabetes Res       Date:  2020-06-19       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.